
1.1K
Downloads
60
Episodes
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Episodes
2 hours ago
2 hours ago
7 min
E71 | 8 min | Latest | Publication Link
- Podcast based on: Markey, G.E.; Langabeer, S.E. Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms. Cancers 2026, 18, 3397. https://doi.org/10.3390/cancers18203397
Type: Review | Publication date: 20 October 2026 - Summary: The classical BCR::ABL1 negative myeloproliferative neoplasms (MPN) are predominantly driven by mutations in three genes: JAK2, CALR, and MPL. Detection and quantitation of these mutations is important for disease diagnosis and monitoring. This review explores molecular methods used to monitor measurable residual disease (MRD) in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) by tracking these mutations. Polymerase chain reaction (PCR)-based tests have been widely adopted, while emerging techniques like droplet digital PCR (ddPCR) can detect extremely low levels of mutations with high accuracy. Next-generation sequencing (NGS) provides a broader insight into genetic changes, helping identify additional mutations linked to disease progression or treatment resistance. Improvements in sensitivity are likely to further the use of NGS approaches for MRD monitoring. These evolving methods will allow for greater scope for disease monitoring in the setting of established and novel emerging therapeutic modalities.
- Keywords: myeloproliferative neoplasm; NGS; ddPCR; polycythemia vera; essential thrombocythemia; primary myelofibrosis
License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.
2 hours ago
7 min

No comments yet. Be the first to say something!